---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-25-000017"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T21:11:33.920950+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Akebia Q4 net loss $22.8M; expects Vafseo Q1 2025 revenue ~$10-11M

## Summary
- Total revenues Q4 $46.5M, down 17% YoY; Auryxia net revenue $44.4M vs $53.2M.
- Net loss Q4 $22.8M vs net income $0.6M; FY2024 net loss $69.4M vs $51.9M.
- Vafseo launch: shipments began Jan 9; >500 prescribers through Feb; Q1 revenue guidance $10-11M.
- Cash $51.9M at Dec 31; post-year-end raised $18.4M ATM + $9.3M BlackRock; funded ≥2 years.
- Plan to initiate Phase 3 VALOR trial for vadadustat in non-dialysis CKD in H2 2025.

## SEC filing metadata
- accession: 0001517022-25-000017
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702225000017/0001517022-25-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702225000017/akba-20250313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-25-000017
- JSON: https://secwatch.observer/filing/0001517022-25-000017.json
- Plain text: https://secwatch.observer/filing/0001517022-25-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.